These findings suggest that although the histologic and current molecular criteria cover a large extent of the glioblastoma diagnosis, some cases in subgroups with lower TERT promoter mutation and chromosome 7+ and 10− incidence, especially from the G5/PDGFRA subgroup but possibly also from the G3/NF1, G3/MMR, G6/Multi-RTK and G7/Other subgroups, may require additional molecular diagnosis criteria. This evidence concerns the gene PDGFRA and glioblastoma.